Cargando…
Impact of continued administration of tolvaptan on cirrhotic patients with ascites
BACKGROUND: The vasopressin V2-receptor antagonist tolvaptan is used to treat cirrhotic patients with ascites. We investigated the outcome of long-term treatment. METHODS: This was a single-center retrospective study. Overall, 170 cirrhotic patients (95 males, median age 63 years) were enrolled and...
Autores principales: | Kogiso, Tomomi, Sagawa, Takaomi, Kodama, Kazuhisa, Taniai, Makiko, Tokushige, Katsutoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299627/ https://www.ncbi.nlm.nih.gov/pubmed/30563565 http://dx.doi.org/10.1186/s40360-018-0277-3 |
Ejemplares similares
-
Risk and protective factors of acute kidney injury in decompensated cirrhotic patients with ascites on tolvaptan
por: Kogiso, Tomomi, et al.
Publicado: (2021) -
The Outcome of Cirrhotic Patients with Ascites Is Improved by the Normalization of the Serum Sodium Level by Tolvaptan
por: Kogiso, Tomomi, et al.
Publicado: (2017) -
Hepatocellular carcinoma after direct‐acting antiviral drug treatment in patients with hepatitis C virus
por: Kogiso, Tomomi, et al.
Publicado: (2018) -
Long‐term outcome of Wilson's disease complicated by liver disease
por: Arai, Satoko, et al.
Publicado: (2021) -
Characteristics of NAFLD Based on Hypopituitarism
por: Kodama, Kazuhisa, et al.
Publicado: (2020)